Journal article
Nilotinib-induced vasculopathy: Identification of vascular endothelial cells as a primary target site
- Abstract:
-
The BCR/ABL1 inhibitor Nilotinib is increasingly used to treat patients with chronic myeloid leukemia (CML). Although otherwise well-tolerated, Nilotinib has been associated with the occurrence of progressive arterial occlusive disease (AOD). Our objective was to determine the exact frequency of AOD and examine in vitro and in vivo effects of Nilotinib and Imatinib on endothelial cells to explain AOD-development. In contrast to Imatinib, Nilotinib was found to upregulate pro-atherogenic adhes...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
Bibliographic Details
- Publisher:
- Springer Nature Publisher's website
- Journal:
- Leukemia Journal website
- Volume:
- 31
- Issue:
- 11
- Pages:
- 2388–2397
- Publication date:
- 2017-09-08
- Acceptance date:
- 2017-07-17
- DOI:
- EISSN:
-
1476-5551
- ISSN:
-
0887-6924
Item Description
- Language:
- English
- Pubs id:
-
pubs:710904
- UUID:
-
uuid:39785be9-6ad0-4d2c-829e-248797f10938
- Local pid:
- pubs:710904
- Source identifiers:
-
710904
- Deposit date:
- 2017-08-07
Terms of use
- Copyright holder:
- Hadzijusufovic et al
- Copyright date:
- 2017
- Notes:
- This is the accepted manuscript version of the article. The final version is available online from Springer Nature at: https://doi.org/10.1038/leu.2017.245
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record